More than 40% of patients with long COVID experience “fibromyalgia-like,” multisite pain, according to data released by Tonix Pharmaceuticals.
The data — the result of an observational, retrospective database study involving more than 50,000 patients with long COVID symptoms — also demonstrate that a high rate of participants reported opioid use, according to the company.
“We undertook this retrospective analysis in part to determine the feasibility and representative nature of our upcoming phase 2 study of TNX-102 SL in patients with long COVID who present with